Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene.
about
Chronic Glutamate Toxicity in Neurodegenerative Diseases-What is the Evidence?Mouse models of polyglutamine diseases: review and data table. Part IStriatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicityTemporal separation of aggregation and ubiquitination during early inclusion formation in transgenic mice carrying the Huntington's disease mutationMouse models of Huntington's disease and methodological considerations for therapeutic trials.A neuroprotective phase precedes striatal degeneration upon nucleolar stress.Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington's disease: neuronal selectivity and potential neuroprotective role of HAP1.Mutant huntingtin can paradoxically protect neurons from death.Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease.Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders.Differential loss of thalamostriatal and corticostriatal input to striatal projection neuron types prior to overt motor symptoms in the Q140 knock-in mouse model of Huntington's disease.In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's Disease.Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function.Comparison of mHTT Antibodies in Huntington's Disease Mouse Models Reveal Specific Binding Profiles and Steady-State Ubiquitin Levels with Disease DevelopmentThe group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease miceExpression of mutant huntingtin in glial cells contributes to neuronal excitotoxicityThe use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies.Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background.Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice.Loss of corticostriatal and thalamostriatal synaptic terminals precedes striatal projection neuron pathology in heterozygous Q140 Huntington's disease mice.Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of diseaseMitochondrial calcium function and dysfunction in the central nervous system.The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?Brain networks in Huntington disease.Huntington's disease: can mice lead the way to treatment?The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition.Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of diseaseNeuronal Ca(2+) dyshomeostasis in Huntington disease.A mitochondrial basis for Huntington's disease: therapeutic prospects.Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's Disease.Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status.Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice.Calcium-dependent cleavage of endogenous wild-type huntingtin in primary cortical neurons.Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice.Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A.Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.Corticostriatal synaptic function in mouse models of Huntington's disease: early effects of huntingtin repeat length and protein load.Disrupted striatal neuron inputs and outputs in Huntington's disease.
P2860
Q26770781-27E79366-4329-4961-95AB-E08C27873E26Q26853025-D6CA80EF-066D-4A77-81EF-89296AC645A6Q28239309-78847E91-5DE3-4366-BDBC-49E37D37E914Q28728849-17F1CB49-6218-4841-9259-91189A47605BQ30481208-D4444693-A8E7-42AE-980A-E340924FEBBEQ30549660-5025B4A8-5E26-4F84-903C-BA81008EE9A2Q31129663-D161F8E3-25A8-4DAA-9C5F-761B99B0BD03Q33304630-3F0F56B4-147A-4776-99BC-66DF10BB82C2Q34126315-8FE2322D-170B-4F5B-AAFE-9D74C2EF26B8Q34233293-5E9D54AA-13B9-4C48-BDA3-3A035DD0DE46Q34341619-FE4584E3-AFCD-4CF8-AE34-3E4AB02B71A6Q35116551-37FE7398-19A7-4858-A420-6D626E55DCC3Q35161675-B281F110-CE6F-46F9-B558-353511376091Q36022756-F7B79E2B-736B-4D02-BAB9-C93B20E4BF79Q36037085-9F513C20-7E26-4322-AF21-EE934A916BF5Q36320596-2ACFC929-1F41-49A5-BB73-57B3D171EED9Q36358871-CF237A68-F294-4C56-BAB6-17FD37EFE479Q36861129-6A4B07EF-D5FE-4FAC-8169-ACA98560776CQ36984277-7329B8A6-1133-4695-95EC-1042CCB94085Q37131550-45E93C90-E638-4A29-90F3-0A360A6A173EQ37255018-97C31B78-341F-4D4C-80F7-A05CE7EDA6BEQ37311202-86AC42CA-AD53-4075-B3D6-AC9B192997A5Q37418288-C754D25D-7680-499F-9E42-174F8C383819Q37441183-2BB20AD5-1B17-4FF7-BBCD-59EA80EF3471Q37834193-2AD8B8FF-DB31-4EC9-8095-6B8E9C6CE1C9Q37840353-94716EFC-924B-46A6-B444-4403A34E88D2Q37921617-391327E0-2300-4865-81F3-FB3B820EAC7CQ37930190-1454C79E-C68D-4A2D-B3F1-6D2D4698DCB4Q37996350-DBA4FB70-1DF8-4C01-92DF-346E0043D6C8Q38074521-B102733C-1FCD-4F61-9327-C1C9042D2EEBQ38174451-B06C3AAA-7920-45CC-A126-E084C0709332Q39217739-1A8BDA2F-67BA-4532-97AF-115E8B2E899FQ41350923-6F7EC88D-3E64-4DE3-BADB-CFF76D60CBE0Q42671677-D131DF68-80D7-45ED-8BEC-498A453071F9Q44117680-7D08076C-7330-478C-B3E9-408FCDEE0424Q44405624-A78155EC-7473-44CF-9F4B-96F028D82EB8Q45194978-3F73797C-D7A6-45F3-98CE-5273C697198DQ45295696-5F979B27-C9D8-4EF6-8E1F-B770A6CD8686Q45306738-891019B4-E1AF-4D70-B4D8-26542125DF38Q52690256-B2897F2E-70A4-4CD0-9635-4E1CA49C6A61
P2860
Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Resistance to NMDA toxicity co ...... exon 1 of the huntington gene.
@en
Resistance to NMDA toxicity co ...... exon 1 of the huntington gene.
@nl
type
label
Resistance to NMDA toxicity co ...... exon 1 of the huntington gene.
@en
Resistance to NMDA toxicity co ...... exon 1 of the huntington gene.
@nl
prefLabel
Resistance to NMDA toxicity co ...... exon 1 of the huntington gene.
@en
Resistance to NMDA toxicity co ...... exon 1 of the huntington gene.
@nl
P2093
P2860
P1476
Resistance to NMDA toxicity co ...... exon 1 of the huntington gene.
@en
P2093
P2860
P304
P356
10.1046/J.0953-816X.2001.01767.X
P407
P577
2001-11-01T00:00:00Z